Raras
Buscar doenças, sintomas, genes...
Doença de von Hippel-Lindau
ORPHA:892CID-10 · Q85.8CID-11 · 5A75OMIM 193300DOENÇA RARA

Doença autossômica dominante causada por variantes patogênicas no gene VHL, levando a um risco aumentado de vários tumores benignos e malignos, incluindo hemangioblastomas, hemangiomas retinais, tumores do saco endolinfático, carcinoma de células renais e feocromocitomas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença autossômica dominante causada por variantes patogênicas no gene VHL, levando a um risco aumentado de vários tumores benignos e malignos, incluindo hemangioblastomas, hemangiomas retinais, tumores do saco endolinfático, carcinoma de células renais e feocromocitomas.

Pesquisas ativas
21 ensaios
60 total registrados no ClinicalTrials.gov
Publicações científicas
2.435 artigos
Último publicado: 2026 Apr 13
Medicamentos
6 registrados
BELZUTIFAN, VATALANIB, PAZOPANIB HYDROCHLORIDE

Tem tratamento?

6 medicamentos registrados
Ver detalhes, fases e interações →
BELZUTIFANVATALANIBPAZOPANIB HYDROCHLORIDEPAZOPANIBDOVITINIBSUNITINIB

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.1
United Kingdom
Início
Adolescent
+ adult, childhood
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q85.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
6 sintomas
❤️
Coração
5 sintomas
🫃
Digestivo
5 sintomas
🫘
Rins
4 sintomas
🧠
Neurológico
2 sintomas
💪
Músculos
2 sintomas

+ 18 sintomas em outras categorias

Características mais comuns

97%prev.
Deficiência auditiva neurossensorial
Frequência: 34/35
90%prev.
Anormalidade do olho
Muito frequente (99-80%)
77%prev.
Zumbido
Frequência: 27/35
69%prev.
Vertigem
Ocasional (29-5%)
55%prev.
Carcinoma de células renais
Frequente (79-30%)
55%prev.
Hemangioblastoma cerebelar
Frequente (79-30%)
49sintomas
Muito frequente (2)
Frequente (8)
Ocasional (25)
Muito raro (8)
Sem dados (6)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 49 características clínicas mais associadas, ordenadas por frequência.

Deficiência auditiva neurossensorialSensorineural hearing impairment
Frequência: 34/3597%
Anormalidade do olhoAbnormality of the eye
Muito frequente (99-80%)90%
ZumbidoTinnitus
Frequência: 27/3577%
VertigemVertigo
Ocasional (29-5%)69%
Carcinoma de células renaisRenal cell carcinoma
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.435PubMed
Últimos 10 anos200publicações
Pico2025125 papers
Linha do tempo
2026Hoje · 2026🧪 1990Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

VHLvon Hippel-Lindau disease tumor suppressorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed:10944113, PubMed:17981124, PubMed:19584355). Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions (PubMed:10944113, PubMed:17981124). Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases (PubMed:10944113, PubMed:1

LOCALIZAÇÃO

CytoplasmCell membraneEndoplasmic reticulumNucleus

VIAS BIOLÓGICAS (6)
Antigen processing: Ubiquitination & Proteasome degradationOxygen-dependent proline hydroxylation of Hypoxia-inducible Factor AlphaNeddylationReplication of the SARS-CoV-1 genomeReplication of the SARS-CoV-2 genome
MECANISMO DE DOENÇA

Pheochromocytoma

A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
47.6 TPM
Fibroblastos
30.1 TPM
Cérebro - Hemisfério cerebelar
29.8 TPM
Baço
24.1 TPM
Cervix Endocervix
22.7 TPM
OUTRAS DOENÇAS (6)
pheochromocytomavon Hippel-Lindau diseasenonpapillary renal cell carcinomaChuvash polycythemia
HGNC:12687UniProt:P40337
CCND1G1/S-specific cyclin-D1Modifying germline mutation inRestrito
FUNÇÃO

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:1827756, PubMed:1833066, PubMed:19412162, PubMed:33854235, PubMed:8114739, PubMed:8302605). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression

LOCALIZAÇÃO

NucleusCytoplasmNucleus membrane

VIAS BIOLÓGICAS (9)
Cyclin D associated events in G1PTK6 Regulates Cell CycleSCF(Skp2)-mediated degradation of p27/p21SPOP-mediated proteasomal degradation of PD-L1(CD274)Transcriptional Regulation by VENTX
OUTRAS DOENÇAS (5)
B-cell chronic lymphocytic leukemiaplasma cell myelomavon Hippel-Lindau diseasemantle cell lymphoma
HGNC:1582UniProt:P24385

Medicamentos e terapias

BELZUTIFANPhase 4

Mecanismo: Endothelial PAS domain-containing protein 1 inhibitor

VATALANIBPhase 2

Mecanismo: Vascular endothelial growth factor receptor inhibitor

PAZOPANIB HYDROCHLORIDEPhase 2

Mecanismo: Vascular endothelial growth factor receptor inhibitor

PAZOPANIBPhase 2

Mecanismo: Vascular endothelial growth factor receptor inhibitor

DOVITINIBPhase 2

Mecanismo: Fibroblast growth factor receptor 3 inhibitor

SUNITINIBPhase 2

Mecanismo: Vascular endothelial growth factor receptor inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

760 variantes patogênicas registradas no ClinVar.

🧬 CCND1: GRCh37/hg19 11q12.2-13.5(chr11:59923608-76272324)x3 ()
🧬 CCND1: NC_000011.9:g.(?_64973914)_(70052579_?)dup ()
🧬 CCND1: GRCh37/hg19 11p13-q25(chr11:32799481-134938470)x3 ()
🧬 CCND1: GRCh37/hg19 11q13.3-13.4(chr11:69214835-70821137)x1 ()
🧬 CCND1: Single allele ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 31
2Fase 210
1Fase 11
·Pré-clínico13
Medicamentos catalogadosEnsaios clínicos· 6 medicamentos · 20 ensaios
✓ Aprovados — podem ser usados hoje
BELZUTIFAN
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de von Hippel-Lindau

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

17 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

60 ensaios clínicos encontrados, 21 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Ensaio clínico
Timeline de publicações
842 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 842

#1

Whole-Genome Landscape of Retinal Hemangioblastomas.

Translational vision science &amp; technology2026 Jan 05

Retinal hemangioblastomas (RHs) are rare benign vascular tumors that present mostly as manifestations of Von Hippel-Lindau (VHL) syndrome. In contrast to other VHL syndrome-associated tumors, only a handful of molecular studies have been published on RHs. It remains unclear whether VHL alterations alone drive RH tumorigenesis. Whole-genome sequencing (WGS) was performed on germline- and RHs-derived DNA of five patients. Additionally, transcriptomes of four unaffected retinas and five choroid controls were compared with those of RH biopsies. Heterozygous germline missense variants and copy number losses impacting VHL were identified. In all RH biopsies, mosaic loss of chromosome 3 was present, indicating the "second hit" in RHs is likely loss of the complete wild-type chromosome 3. Few additional somatic short nucleotide variants (SNVs) indels, or structural variants with deleterious potential were detected, suggesting that somatic changes are rare but not limited to the VHL gene region. RNA sequencing revealed reduced VHL expression in tumor tissue and downstream gene expression changes consistent with loss of VHL expression. RHs have few somatic changes. Loss of chromosome 3 is likely the second hit in RHs with germline VHL alterations. RHs are benign neoplasms with little somatic changes compared with other VHL-syndrome associated tumors. Variants affecting VHL impact downstream gene expression, variants impacting different VHL domains result in differential gene expression of these downstream targets. RNA sequencing may aid in the evaluation of variants of unknown significance.

#2

Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review.

Pediatric blood &amp; cancer2026 Mar

The combination of disease manifestations, the familial burden, and varying penetrance of endocrine tumor syndromes (ETSs) is unique. This review aimed to portray and summarize available data on psychosocial outcomes in patients with ETSs and explore gaps and opportunities for future research and care. Literature was systematically searched for articles on psychosocial outcomes in patients with multiple endocrine neoplasia (MEN), von Hippel-Lindau (VHL), and pathogenic variants (PVs) in succinate dehydrogenase (SDHx) genes via PubMed, PsychInfo, and Embase. Study quality was assessed using the CASP and STROBE appraisal tools. In total, 36 studies were found with fluctuating levels of evidence, of which five included pediatric patients. Overall, studies showed a considerable impact of ETSs on psychosocial outcomes such as quality of life (QoL), anxiety, and depression. Maladaptive coping, as well as social and financial restraints, were associated with poorer psychosocial outcomes. Surveillance protocols had ambivalent effects, both creating a sense of control and serving as a constant reminder of having an ETS. Parathyroid disease was associated with adverse psychosocial effects in MEN1. In MEN2A, gastrointestinal symptoms and having affected offspring were associated with poorer psychosocial outcomes. In MEN2B, pain was reported to interfere with daily life. Studies regarding VHL reported a wide range of experiences in patients and family members. Only a few studies were found for patients with PVs in SDHx genes, mainly describing effects due to the manifestation of disease or paraganglioma. Psychosocial outcomes and possible underlying factors seem different for each ETS. More research is needed to address psychosocial outcomes in children with an ETS.

#3

Pancreatic Involvement in von Hippel Lindau Disease: A Single-Center Experience.

JGH open : an open access journal of gastroenterology and hepatology2026 Feb
#4

Somatic mutational landscape in von Hippel-Lindau familial hemangioblastoma.

Molecular oncology2026 Mar 23

Von Hippel-Lindau disease (vHL) predisposes to tumor development, mainly clear cell renal carcinoma and hemangioblastoma. The underlying cause is germline variants in the VHL gene, with tumorigenesis thought to require additional somatic 'second-hit' events that most commonly include loss of 3p. However, the precise mechanisms of vHL-related tumor development remain incompletely understood. Genomic investigations of familial hemangioblastoma may help elucidate the early steps of tumorigenesis and contribute to improved disease prediction, biomarker discovery, and therapeutic strategies. We performed whole exome sequencing on 22 familial hemangioblastomas from 7 patients representing 5 unrelated families, and with 4 different causative VHL genotypes. The tumors exhibited low overall mutational burden but showed frequent loss of heterozygosity on chromosome 3 or 3p and single nucleotide variants in the VHL region. Variants were significantly enriched in genes associated with GABAergic and serotonergic neuronal cell types, as well as in pathways regulating cell cycle and neurogenesis. These findings suggest that, in addition to VHL loss, dysregulation of neuronal differentiation programs and cell cycle control may play important roles in hemangioblastoma tumorigenesis.

#5

[Calcinosis cutis in a hemodialysis patient with Von Hippel-Lindau disease].

Nephrologie &amp; therapeutique2026 Mar 11

We report the case of a 52-year-old man with Von Hippel-Lindau disease who had been receiving nocturnal home hemodialysis for ten months following bilateral nephrectomy for multifocal clear cell renal carcinoma. He presented with a firm, painless subcutaneous nodule on the right anterior thigh, featuring a central crater filled with chalky-white material. Skin biopsy revealed dermal calcium deposits surrounded by a fibrous and histiocytic reaction, consistent with dystrophic calcinosis cutis. Additional nodules were palpable on the left calf and right biceps. Bilateral femur X-rays were normal. Persistent hyperphosphatemia and inadequate dialysis likely contributed to the development of these extraosseous calcifications. Management included intensification of phosphate binder therapy and increased dialysis frequency. This case illustrates the potential interplay between hereditary tumor syndromes and dialysis-related mineral metabolism disorders, highlighting the risk of severe extraosseous calcifications in such patients. Nous rapportons le cas d’un homme de 52 ans atteint de la maladie de Von Hippel-Lindau, traité par hémodialyse nocturne à domicile depuis dix mois, après néphrectomie bilatérale pour carcinome rénal à cellules claires multifocal. Il signale l’apparition d’un nodule sous-cutané ferme et indolore de la cuisse droite, avec un cratère central rempli de matériel blanchâtre. La biopsie cutanée a révélé des dépôts calciques dermiques entourés d’une réaction fibreuse et histiocytaire, compatible avec une calcinose cutanée dystrophique. D’autres nodules suspects étaient palpables sur le mollet gauche et le biceps droit. La radiographie des fémurs était normale. L’hyperphosphatémie persistante et un contexte de dialyse insuffisante ont probablement contribué à la survenue de ces calcifications extra-osseuses. L’intensification du traitement chélateur du phosphate et une augmentation de la fréquence des séances d’hémodialyse ont été mises en œuvre. Ce cas illustre l’interaction potentielle entre pathologies tumorales héréditaires et troubles phosphocalciques liés à la dialyse.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.449 artigos no totalmostrando 196

2026

Somatic mutational landscape in von Hippel-Lindau familial hemangioblastoma.

Molecular oncology
2026

[Calcinosis cutis in a hemodialysis patient with Von Hippel-Lindau disease].

Nephrologie &amp; therapeutique
2026

Neurogenetic tumor syndromes: The current landscape of workup and treatment.

Neuro-oncology practice
2026

"I don't think I even thought of myself" A mixed-methods study of family experiences of trio germline whole genome sequencing in newly diagnosed childhood cancer.

British journal of cancer
2026

Bilateral multifocal renal neuroendocrine carcinoma with synchronous pancreatic neuroendocrine carcinoma and adrenal lesion.

Journal of surgical case reports
2026

Pancreatic Involvement in von Hippel Lindau Disease: A Single-Center Experience.

JGH open : an open access journal of gastroenterology and hepatology
2026

Cancer predisposition syndromes: an imaging review.

Cancer imaging : the official publication of the International Cancer Imaging Society
2026

5' UTR length regulates alternative N-terminal protein isoform production in health and disease.

bioRxiv : the preprint server for biology
2025

[A Family case of von Hippel-Lindau syndrome].

Problemy endokrinologii
2026

Persistent Hypercalcemia: Diagnostic Complexity With Multiglandular Hyperparathyroidism, Renal Cell Carcinoma, and Hereditary Tumor Features.

Cureus
2026

Hereditary Renal Cancer Syndromes: Clinicopathologic Features and Correlation With Tumors Harboring Somatic Mutations.

Advances in anatomic pathology
2026

Exploring the Illness Experience of Patients with Central Nervous System Hemangioblastomas in Von Hippel-Lindau Disease: A Qualitative Study.

Healthcare (Basel, Switzerland)
2026

Bilateral pheochromocytomas with locally advanced right adrenal tumor extending into the inferior vena cava in a suspected Von Hippel-Lindau syndrome: A case report.

Urology case reports
2026

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.

Cancer chemotherapy and pharmacology
2026

Whole-Genome Landscape of Retinal Hemangioblastomas.

Translational vision science &amp; technology
2026

Expanding the clinical tumor phenotype of the EPAS1-asssociated tumor syndrome.

The Journal of clinical endocrinology and metabolism
2026

Hereditary renal cell carcinoma surveillance protocols: a review of the literature and proposed recommendations.

Familial cancer
2026

Distinct genomic, microenvironmental, and nephron signatures in VHL kidney cysts and tumors.

Scientific reports
2026

The European medicines agency review of belzutifan (Welireg) for the treatment of adult patients with von Hippel-Lindau disease-associated tumors.

The oncologist
2026

Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review.

Pediatric blood &amp; cancer
2025

Role of Targeted Therapy in the Management of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: A Single-Proportion Meta-Analysis.

Cureus
2025

[Chinese expert consensus for the diagnosis and treatment of von Hippel-Lindau syndrome (2025 edition)].

Zhonghua yi xue za zhi
2025

Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.

Current oncology (Toronto, Ont.)
2025

Integrating whole-exome sequencing and scRNA-seq reveal the characteristic in one clear cell renal cell carcinoma sample arising in the setting of VHL disease.

Scientific reports
2025

Anesthetic Management of a Cesarean Section in a Parturient With Von Hippel-Lindau Disease.

Cureus
2025

Belzutifan for Ocular Tumors in Patients with von Hippel-Lindau Disease.

Ocular oncology and pathology
2025

Prognostic relevance of MIB-1 labeling index in VHL-associated and sporadic spinal hemangioblastomas: a subgroup analysis from a multicentric study.

Acta neuropathologica communications
2026

Percutaneous Cryoablation With Lipiodol Marking for Hereditary Renal Cell Carcinomas: Cancer Control and Renal Functional Outcomes.

International journal of urology : official journal of the Japanese Urological Association
2025

Dysregulation of the ubiquitin-proteasome system in von Hippel-Lindau syndrome: molecular insights and clinical perspectives.

Clinical and experimental medicine
2025

From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004.

Translational andrology and urology
2025

From surgery to systemic therapy: long-term lessons of belzutifan in von Hippel-Lindau disease.

Translational andrology and urology
2025

Adrenergic Storm with Obstructive Hydrocephalus: Atypical Neurological Presentation of Von Hippel-Lindau Disease with Bilateral Pheochromocytoma in an Adolescent.

Journal of the ASEAN Federation of Endocrine Societies
2025

Near-infrared carbon dots enable ultra-sensitive fluorometric detection of belzutifan: a novel approach for real-time therapeutic drug monitoring in cancer treatment.

Analytical methods : advancing methods and applications
2025

Familial Von Hippel-Lindau Disease: A Case Series of Cerebral Hemangioblastomas with MRI, Histopathological, and Genetic Correlations.

Life (Basel, Switzerland)
2025

Von Hippel-Lindau Disease-Associated Endolymphatic Sac Tumours: Seven Cases and Genotype-Phenotype Features.

Current oncology (Toronto, Ont.)
2025

Genetic Testing and Counselling for Hereditary Renal Carcinoma: What Do Clinicians Need to Know?

European urology open science
2025

Clinical challenges of cancer predisposition syndromes with pediatric central nervous system tumors: a single-center study.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Re: W. Marston Linehan, Cathy Anne Pinto, Yanfang Liu, et al. Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease. Eur Urol 2025;88:56-63.

European urology
2025

The truth behind multiple neuroendocrine tumors: Von Hippel-Lindau syndrome and its diagnostic challenges-A case report and literature review.

Science progress
2025

Stereotactic radiosurgery as adjuvant or salvage treatment for sporadic hemangioblastomas: A multi-center international study.

Journal of the neurological sciences
2025

Intra- and inter-tumoural heterogeneity in von Hippel-Lindau disease-related renal cancer: a multimodal data study protocol.

European radiology experimental
2025

Long-term HIF-2α inhibition in von Hippel-Lindau disease: insights from LITESPARK-004.

Translational andrology and urology
2026

Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan.

Urologic oncology
2025

Types of pancreatic lesions and the mutational landscape of the VHL gene in patients with von Hippel-Lindau disease.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
2025

Identification of a VHL germline deletion in a family with Von Hippel-Lindau syndrome using MLPA-NGS.

BMC medical genomics
2026

All-in-One Case: Comprehensive Detection of VHL Syndrome With 68 Ga-DOTATATE PET/CT.

Clinical nuclear medicine
2025

Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors - a retrospective single center analysis.

BMC cancer
2025

BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

American journal of human genetics
2025

[Cystic-solid transformation of the pancreas and kidneys due to von Hippel-Lindau disease].

Khirurgiia
2025

Canine Hemangioblastoma: Case Series and Literature Review.

Animals : an open access journal from MDPI
2025

Computed tomography-guided radiofrequency ablation of pheochromocytomas in a small case series with von Hippel-Lindau disease: treatment safety and outcomes.

Abdominal radiology (New York)
2025

Multisystemic Presentation of Von Hippel-Lindau Disease Revealed by Pheochromocytoma and Takotsubo Syndrome.

JACC. Case reports
2025

First-in-class oral hypoxia-inducible factor 2α in von Hippel-Lindau disease: a new era of targeted therapy.

Polish archives of internal medicine
2025

Updated 2025 French guidelines for renal cell carcinoma.

The French journal of urology
2025

HIFα isoform specific activities drive cell-type specificity of VHL-associated oncogenesis.

Nature communications
2025

Gross total resection is associated with improvement and prognosis even in von Hippel-Lindau disease-related hemangioblastomas: Nationwide registry in Japan.

Neuro-oncology practice
2026

Collision of Retinitis Pigmentosa and Von-Hippel Lindau Disease.

American journal of ophthalmology
2025

Laparoscopic Left Hepatectomy for Slowly Progressing Primary Hepatic Carcinosarcoma Associated With Von Hippel-Lindau Disease.

Asian journal of endoscopic surgery
2025

Unraveling the impact of VHL exon 2 mutations in erythrocytosis or von Hippel-Lindau disease identified RNA-binding proteins involved in VHL splicing.

American journal of human genetics
2025

Role of PPV in Advanced Retinal Hemangioblastoma-A Systematic Review.

International ophthalmology clinics
2026

Quantitative analysis of the anti-VEGF effect for retinal capillary hemangiomas and vasoproliferative tumors.

European journal of ophthalmology
2025

The gradual expansion of multiple intramedullary metastatic renal cell carcinoma in a patient with von Hippel-Lindau disease with multiple intramedullary hemangioblastomas: illustrative case.

Journal of neurosurgery. Case lessons
2025

Mathematical modeling and simulation of tumor-induced angiogenesis in retinal hemangioblastoma.

PLoS computational biology
2025

Pancreatic Hemangioblastoma in a Patient with von Hippel-Lindau Disease: A Case Report.

Surgical case reports
2025

The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center.

The oncologist
2025

Pancreatic Involvement by Mixed Serous Neuroendocrine Neoplasm Detected by Endosonography With Fine-Needle Tissue Acquisition in Von Hippel-Lindau Disease.

Cureus
2025

Impact of Belzutifan on Pancreatic Cystic Lesions and Neuroendocrine Tumors in Patients With Von Hippel-Lindau Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

Presentation, management, and clinical outcomes of von Hippel-Lindau syndrome.

Hong Kong medical journal = Xianggang yi xue za zhi
2025

Synchronous giant bilateral renal tumors as initial presentation of Von Hippel-Lindau disease: Sequential surgical management and transition to renal replacement therapy.

Urology case reports
2026

Unclassified Renal Cell Carcinoma with Reverse Polarity and Pathogenic von Hippel-Lindau Mutation in a Congenital Renal Malformation.

International journal of surgical pathology
2025

Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations.

International journal of molecular sciences
2025

The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey.

The oncologist
2025

Quantification of Belzutifan in Biological Samples: LC-MS/MS Method Validation and Pharmacokinetic Study in Rats.

Biomedical chromatography : BMC
2025

Proteomic characterization of the pseudocapsule of clear cell renal cell carcinoma in VHL disease reveals a distinct microenvironment at the tumor boundary zone.

Neoplasia (New York, N.Y.)
2025

Von Hippel-Lindau Disease.

Advances in experimental medicine and biology
2025

Tumor-to-Tumor Metastasis in a Patient With Hemangioblastoma Unrelated to von Hippel-Lindau Disease: A Case Report and Review of the Literature.

Cureus
2025

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma.

Urology
2025

Detection of VHL variant on multigene panel testing for hereditary breast cancer: Implications for genetic counselling.

Cancer genetics
2026

Incidental Discovery of Synchronous Ileal Neuroendocrine Tumors at Fluorodopa PET/CT in a Patient With Bilateral Pheochromocytoma.

Clinical nuclear medicine
2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma.

International journal of clinical oncology
2025

Anesthetic challenges in a pregnant patient with Von Hippel-Lindau disease: A case report.

Saudi journal of anaesthesia
2025

Case report: Nephrotic syndrome induced by Lenvatinib treatment in a patient with von Hippel-Lindau syndrome.

BMC nephrology
2025

Papillary endolymphatic sac tumor: Case report with clinical study and therapeutic management.

International journal of surgery case reports
2025

Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors - Authors' reply.

The Lancet. Oncology
2025

Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors.

The Lancet. Oncology
2025

Analysis of BRCA1, BRCA2 and PALB2 related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

medRxiv : the preprint server for health sciences
2025

Bilateral Pheochromocytoma in a Child Revealing Von Hippel-Lindau Disease.

Cureus
2025

Von Hippel-Lindau disease caused obstructive jaundice.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2026

Outcomes After Stereotactic Radiosurgery for Intracranial Hemangioblastoma in Von Hippel-Lindau Disease and Sporadic Cases: An International Multicenter Study.

Neurosurgery
2025

Corrigendum to "Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance" by Jung et al. (J Korean Neurosurg Soc 68 : 338-349, 2025).

Journal of Korean Neurosurgical Society
2025

When is belzutifan the right option for von Hippel-Lindau disease-associated hemangioblastomas?-a critical review of LITESPARK-004 results.

Translational cancer research
2025

Leptomeningeal hemangioblastoma: illustrative case.

Journal of neurosurgery. Case lessons
2025

A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database.

International journal of clinical pharmacy
2025

Genotype-phenotype correlation in Iranian retinal hemangioblastoma patients and genetic diagnosis algorithm for Von Hippel-Lindau disease.

Ophthalmic genetics
2025

Bilateral simultaneous laparoscopic clipless adrenal-sparing surgery for pheochromocytoma in a pediatric patient: A case report.

Urology case reports
2025

CRISPR/Cas9-mediated editing of VHL in induced pluripotent stem cells: A model for early cell fate in von Hippel-Lindau syndrome.

Stem cell research
2025

Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study.

Cardiovascular diabetology
2024

Unilateral Pheochromocytoma in Von Hippel-Lindau Syndrome Revealed by a Hemangioblastoma.

Kathmandu University medical journal (KUMJ)
2025

Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures.

Biomedicines
2025

Bilateral Pheochromocytoma with a Novel Pathogenic Variant in the MAX gene: A Case Report.

Journal of the ASEAN Federation of Endocrine Societies
2025

Spinal Hemangioblastoma: The Role of Imaging Characteristics in Preoperative Diagnosis and Surgical Planning.

Cureus
2025

Fibroblast growth factor receptor expression in hemangioblastomas: A novel therapeutic target.

PloS one
2025

Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastoma.

ESMO open
2025

When Evidence Falls Short-Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal.

PharmacoEconomics
2025

Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.

Clinical genitourinary cancer
2025

Pediatric and adolescent von Hippel-Lindau disease: tumor profiles, genotype-phenotype correlation and comparison with adults.

Journal of endocrinological investigation
2025

Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease.

European urology
2025

Genetics and current research models of Mendelian tumor predisposition syndromes with ocular involvement.

Progress in retinal and eye research
2025

[Clinical characterization in patients with neurocutaneous syndrome].

Revista medica del Instituto Mexicano del Seguro Social
2025

Novel OCT Angiography Features, von Hippel-Lindau Disease Association, and Genetic Characterization of Juxtapapillary Retinal Capillary Hemangiomas.

Investigative ophthalmology &amp; visual science
2025

Update on Surveillance in Von Hippel-Lindau Disease.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

The Lancet. Oncology
2025

Belzutifan in von Hippel-Lindau disease.

The Lancet. Oncology
2025

Retinal vascular proliferation with fibrotic regression in von Hippel-Lindau disease.

Taiwan journal of ophthalmology
2025

A Corticotropin-Secreting Adenoma in the Setting of von Hippel-Lindau Disease.

JCEM case reports
2025

Genotype-specific neoplastic risk profiles in patients with VHL disease.

Endocrine-related cancer
2025

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
2025

Bilateral papillary cystadenoma of the broad ligament: a manifestation of Von Hippel-Lindau disease: a case report.

Journal of medical case reports
2025

Urinary leak after partial nephrectomy: Insights from a cohort with hereditary, multifocal, and reoperative cases.

Urologic oncology
2025

Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis.

Seminars in cancer biology
2025

Factors that predict progression of von Hippel-Lindau disease-related malignancy: a longitudinal cohort study.

BMC cancer
2025

Very early-onset symptomatic CNS haemangioblastoma in Von Hippel-Lindau disease.

Journal of medical genetics
2025

Mosaic Form of von Hippel-Lindau Syndrome: Case Report and Literature Review.

International journal of molecular sciences
2026

Resection of a Cervical Spine Hemangioblastoma in Von Hippel-Lindau Disease: 2-Dimensional Operative Video.

Operative neurosurgery (Hagerstown, Md.)
2025

Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance.

Journal of Korean Neurosurgical Society
2025

Pancreatic Serous Neoplasm and Metastatic Clear Cell Renal Cell Carcinoma: Diagnostic Pitfalls Resolvable by a Panel of Immunohistochemical Stains to Include PAX8 and CK7 But Not CAIX.

The American journal of surgical pathology
2025

Stereotactic radiosurgery in the management of central nervous system hemangioblastomas: a systematic review and meta-analysis.

Neurosurgical review
2025

Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease.

Urology
2025

Recanalization and interventional stenting of a closed ductus arteriosus in pulmonary hypertension associated with von Hippel-Lindau disease: a case report.

Cardiology in the young
2025

"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype.

The oncologist
2025

Von Hippel-Lindau syndrome with bilateral renal and an interaortocaval mass.

BMJ case reports
2025

Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies.

Molecular biology reports
2025

First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland.

Current oncology (Toronto, Ont.)
2025

Vasoproliferative Retinal Tumors: Manifestations, Management, and Outcomes in a Case Series.

Case reports in ophthalmology
2025

Delivering Trio Germline Whole Genome Sequencing to Patients Newly Diagnosed With Childhood Cancer: Healthcare Professionals' Perspectives of the PREDICT Study.

Cancer medicine
2025

Local tumor control and neurological outcomes after surgery for spinal hemangioblastomas in sporadic and von Hippel-Lindau disease: A multicenter study.

Neuro-oncology
2025

Pathogenicity of germline VHL variants is associated with renal cell carcinoma size in von Hippel-Lindau disease.

Archives of endocrinology and metabolism
2025

[Retinal vasoproliferative tumor (retinal reactive astrocytic tumor)].

Journal francais d'ophtalmologie
2025

A New Era of Management of Von Hippel-Lindau Disease-Associated Tumors With Belzutifan.

Clinical journal of oncology nursing
2025

Morphology of Retinal Hemangioblastoma in von Hippel-Lindau Disease Revealed by Optical Coherence Tomography Angiography.

Klinische Monatsblatter fur Augenheilkunde
2025

Laparoscopic Partial Nephrectomy for Multiple Complex Renal Masses in a Patient With Von Hippel-Lindau Syndrome: A Case Report.

Cureus
2024

Therapeutic Dilemma of a Juxtapapillary Retinal Capillary Hemangioma.

Cureus
2024

Case report: Endolymphatic sac tumor with blurred vision.

Frontiers in oncology
2024

Relationship between ZHX2 Expression and VHL Gene Alteration in VHL-associated and Sporadic Hemangioblastomas of the Central Nervous System.

Journal of kidney cancer and VHL
2025

Long-term surgical outcomes and prognosis of cervical spinal hemangioblastomas.

Clinical neurology and neurosurgery
2025

Evaluation of Tumor-Infiltrating Leukocytes in Endolymphatic Sac Tumor.

The Laryngoscope
2025

Oral Herpes Simplex Virus Mimicking Tongue Squamous cell Carcinoma in Von Hippel-Lindau Patient: A Case Image.

Head and neck pathology
2025

New Developments in VHL-Associated Neuroendocrine Neoplasms.

Current oncology reports
2025

Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With Von Hippel-Lindau Disease.

Journal of vitreoretinal diseases
2025

Pheochromocytoma in von Hippel-Lindau Disease: Clinical Features and Comparison With Sporadic Pheochromocytoma.

Clinical endocrinology
2025

Genetic syndromes associated with pancreatic neuroendocrine neoplasms and imaging diagnostic strategies.

Abdominal radiology (New York)
2024

Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau?

Journal of kidney cancer and VHL
2024

[Diagnostic and therapeutic perspectives in RASopathies].

Magyar onkologia
2024

[Stereotactic radiotherapy of spinal hemangioblastoma].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2024

Case study of a potential West Polynesian variant of von Hippel-Lindau disease.

The New Zealand medical journal
2024

Generation of TWO iPSC lines (CRICKi009-A; CRICKi010-A) from patients with type 1 von Hippel-Lindau (VHL) and histopathologically confirmed renal cell carcinoma (RCC).

Stem cell research
2025

Surgical Management and Prognostic Factors for Endolymphatic Sac Tumor: A Single-Institute Experience with a Systematic Review.

World neurosurgery
2024

Von Hippel-Lindau disease with ocular and multiple systemic findings.

BMJ case reports
2024

Spinal cord hemangioblastomas in von Hippel-Lindau disease.

Neuro-oncology advances
2024

Current views on the role of HIF-2α in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2024

Comparative analysis of stereotactic radiosurgery outcomes for supratentorial hemangioblastomas in von hippel-lindau disease and sporadic cases: A multi-center international study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2025

Pediatric patients with von Hippel-Lindau and hemangioblastomas treated successfully with belzutifan.

Pediatric blood &amp; cancer
2025

Multisystem diseases in the abdomen and pelvis: imaging manifestations and diagnostic roles of cross-sectional imaging.

Abdominal radiology (New York)
2024

Follow-up report on pulmonary mucosa-associated lymphoma in a patient with von Hippel-Lindau disease.

Journal of surgical case reports
2024

Genotype-phenotype correlation of ocular von Hippel-Lindau disease in Koreans.

PloS one
2024

Familial and early recurrent pheochromocytoma in a child with a novel in-frame duplication variant of VHL.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2024

Unique properties of clinical manifestation and magnetic resonance imaging for differential diagnosis of optic nerve hemangioblastoma.

Eye (London, England)
2024

Application of carbonic anhydrase IX in sporadic hemangioblastoma of the central nervous system and hemangioblastoma associated with von Hippel-Lindau disease.

Clinical neuropathology
2024

Phenotypic and Genotypic Features of a Chinese Cohort with Retinal Hemangioblastoma.

Genes
2024

Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.

Proceedings of the National Academy of Sciences of the United States of America
2024

A novel pathogenic germline chromosome 3 inversion in von Hippel-Lindau disease.

Journal of medical genetics
2024

Hereditary Pheochromocytoma as a Main Manifestation of von Hippel Lindau Disease (vHL) in Childhood - A Long-term Follow-up of 5 Patients with vHL from One Family.

Journal of clinical research in pediatric endocrinology
2025

Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma.

European urology focus
2024

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

The Lancet. Oncology
2024

Genetics, Pathophysiology, and Current Challenges in Von Hippel-Lindau Disease Therapeutics.

Diagnostics (Basel, Switzerland)
2024

Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature.

Ocular oncology and pathology
2024

Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome.

International journal of molecular sciences
2025

Clear Cell Renal Cell Carcinoma: Characterizing the Phenotype of Von Hippel-Lindau Mutation Using MRI.

Journal of magnetic resonance imaging : JMRI
2024

Endolymphatic Sac Tumors Associated With von Hippel-Lindau: A Case Report Highlighting Opportunity for Novel Orphan Drug Therapy.

Otology &amp; neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
2024

Unusual Presentation of Von Hippel-Lindau Syndrome With Gastric Variceal Bleeding.

Cureus
2024

The genetic differences between types 1 and 2 in von Hippel-Lindau syndrome: comprehensive meta-analysis.

BMC ophthalmology
2024

Understanding Adult Central Nervous System Hemangioblastomas: A Systematic Review.

World neurosurgery
2024

The rare diagnosis of Von Hippel-Lindau disease in a 29-year-old patient.

Oman journal of ophthalmology
2024

Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: A systematic review and single-arm meta-analysis.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2024

Clinical T1a Renal Cell Carcinoma with Solitary Diaphragmatic Metastasis in a Patient with von Hippel-Lindau Disease.

Journal of kidney cancer and VHL
2024

Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2α in Hemangioblastomas with Belzutifan.

World neurosurgery
2024

Trigeminal nerve hemangioblastoma in the setting of undiagnosed von Hippel-Lindau disease: illustrative case.

Journal of neurosurgery. Case lessons
2024

Evaluating the Urinary Exosome microRNA Profile of von Hippel Lindau Syndrome Patients with Clear Cell Renal Cell Carcinoma.

Genes
2024

Optic nerve and chiasm hemangioblastomas in von Hippel-Lindau disease: report of 12 cases and review of the literature.

Frontiers in oncology
2024

Portal Venous Thrombosis after Percutaneous Cryoablation for Renal Cell Carcinoma.

Journal of kidney cancer and VHL
2024

Single Stage Bilateral Adrenalectomy (Cortical-Sparing) and Pancreatectomy (Corpus-Sparing) in a Patient with Von Hippel-Lindau Disease.

Sisli Etfal Hastanesi tip bulteni
2024

Optical Coherence Tomography Angiography-Navigated Laser Photocoagulation of Retinal Hemangioblastomas in Patients With von Hippel-Lindau Disease.

Translational vision science &amp; technology
2024

von Hippel-Lindau Syndrome and Secondary Hypertension: A Case Report.

Cureus
2024

Cauda equina myxopapillary ependymoma in von Hippel-Lindau disease: A case report.

Surgical neurology international
2024

Characterization of spinal hemangioblastomas in patients with and without von Hippel-Lindau, and YAP expression.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia
2024

Comprehensive treatment of von Hippel-Lindau disease: A case report.

Cancer innovation
Ver todos os 1.449 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de von Hippel-Lindau.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de von Hippel-Lindau

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Whole-Genome Landscape of Retinal Hemangioblastomas.
    Translational vision science &amp; technology· 2026· PMID 41533848mais citado
  2. Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review.
    Pediatric blood &amp; cancer· 2026· PMID 41491677mais citado
  3. Pancreatic Involvement in von Hippel Lindau Disease: A Single-Center Experience.
    JGH open : an open access journal of gastroenterology and hepatology· 2026· PMID 41709978mais citado
  4. Somatic mutational landscape in von Hippel-Lindau familial hemangioblastoma.
    Molecular oncology· 2026· PMID 41870981mais citado
  5. [Calcinosis cutis in a hemodialysis patient with Von Hippel-Lindau disease].
    Nephrologie &amp; therapeutique· 2026· PMID 41811690mais citado
  6. 5' UTR length shapes alternative N-terminal protein isoforms across cancers and in rare disease.
    EMBO Rep· 2026· PMID 41974896recente
  7. Belzutifan Efficacy in Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma Versus Natural History Control Arm.
    J Natl Cancer Inst· 2026· PMID 41964905recente
  8. Gastric Neuroendocrine Tumor Presenting Atypically in von Hippel-Lindau Disease: A Case Report.
    J Kidney Cancer VHL· 2026· PMID 41948715recente
  9. Atypical, Clinically Silent, Locally Advanced Pheochromocytoma Revealing Von Hippel-Lindau Type 2C Phenotype: A Case Report.
    Cureus· 2026· PMID 41930086recente
  10. Very rapid response to belzutifan of VHL-related intracranial and retinal hemangioblastomas.
    Am J Ophthalmol Case Rep· 2026· PMID 41908298recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:892(Orphanet)
  2. OMIM OMIM:193300(OMIM)
  3. MONDO:0008667(MONDO)
  4. GARD:7855(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q741315(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de von Hippel-Lindau
Compêndio · Raras BR

Doença de von Hippel-Lindau

ORPHA:892 · MONDO:0008667
Prevalência
1-9 / 100 000
Herança
Autosomal dominant
CID-10
Q85.8 · Outras facomatoses não classificadas em outra parte
CID-11
Ensaios
21 ativos
Medicamentos
6 registrados
Início
Adolescent, Adult, Childhood
Prevalência
1.1 (United Kingdom)
MedGen
UMLS
C0019562
EuropePMC
Wikidata
Wikipedia
Papers 10a
Evidência
🥈 Ensaio clínico
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades